Goserelin
- Generic Name
- Goserelin
- Brand Names
- Zoladex
- Drug Type
- Small Molecule
- Chemical Formula
- C59H84N18O14
- CAS Number
- 65807-02-5
- Unique Ingredient Identifier
- 0F65R8P09N
- Background
Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medication is stopped, hormone levels return...
- Indication
Goserelin is indicated for:
- Associated Conditions
- Abnormal Uterine Bleeding, Advanced Breast Cancer, Endometriosis, Advanced carcinoma of the prostate, Stage T2b carcinoma of the prostate, Stage T4 carcinoma of the prostate
- Associated Therapies
- Palliative Treatment
To Assess The Patient Preference for Goserelin Microsphere Versus Goserelin Implant in Patients With Prostate Cancer
- First Posted Date
- 2024-04-26
- Last Posted Date
- 2024-04-26
- Target Recruit Count
- 60
- Registration Number
- NCT06385847
- Locations
- 🇨🇳
The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
Stereotactic Body Radiation Therapy Plus Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy for Treatment of Metastatic, Recurrent Hormone-Sensitive Prostate Cancer, DIVINE Trial
- Conditions
- Interventions
- Drug: AbirateroneDrug: ApalutamideProcedure: Biospecimen CollectionProcedure: Bone ScanProcedure: Computed TomographyDrug: DarolutamideDrug: DegarelixDrug: EnzalutamideDrug: GoserelinDrug: HistrelinDrug: LeuprolideProcedure: Magnetic Resonance ImagingOther: Patient ObservationProcedure: Positron Emission TomographyDrug: PrednisoneOther: Questionnaire AdministrationDrug: RelugolixRadiation: Stereotactic Body Radiation TherapyDrug: Triptorelin
- First Posted Date
- 2024-04-23
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 120
- Registration Number
- NCT06378866
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery
- First Posted Date
- 2024-04-04
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 74
- Registration Number
- NCT06348134
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
To Prevent Type I-II Myoma After TCRM Recurrence by Gonadotropin-releasing Hormone (GnRH )Analogues or Mifepristone
- Conditions
- Interventions
- First Posted Date
- 2023-06-12
- Last Posted Date
- 2023-06-12
- Target Recruit Count
- 294
- Registration Number
- NCT05898321
- Locations
- 🇨🇳
Women's Hospital School of Medicine Zhejiang University, Hangzhou, Zhejiang, China
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-04-24
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 3100
- Registration Number
- NCT05827081
- Locations
- 🇦🇺
Novartis Investigative Site, Gateshead, New South Wales, Australia
Neoadjuvant Endocrine Therapy in Breast Cancer. Real Clinical Practice in Russia
- First Posted Date
- 2023-04-05
- Last Posted Date
- 2023-04-06
- Lead Sponsor
- Blokhin's Russian Cancer Research Center
- Target Recruit Count
- 300
- Registration Number
- NCT05800197
- Locations
- 🇷🇺
Blokhin's Russian Cancer Research Center, Moscow, Russian Federation
Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC
- Conditions
- Interventions
- First Posted Date
- 2023-02-09
- Last Posted Date
- 2024-06-10
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 42
- Registration Number
- NCT05720260
- Locations
- 🇨🇳
Department of Oncology, National Taiwan University Hospital, Taipei City, Taiwan
Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland
- Conditions
- Interventions
- First Posted Date
- 2023-01-26
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1
- Registration Number
- NCT05701007
- Locations
- 🇫🇮
Pfizer, Helsinki, Finland
Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)
- Conditions
- Interventions
- First Posted Date
- 2023-01-23
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- National Cancer Center Hospital East
- Target Recruit Count
- 56
- Registration Number
- NCT05694819
- Locations
- 🇯🇵
Hokkaido University Hospital, Sapporo, Hokkaido, Japan
🇯🇵National Hospital Organization Kyushu Medical Center, Fukuoka, Japan
🇯🇵Tohoku University Hospital, Sendai, Miyagi, Japan
Evaluation of the Effect of Self-Assembling Peptide P11-4
- First Posted Date
- 2022-12-28
- Last Posted Date
- 2023-01-06
- Lead Sponsor
- Egymedicalpedia
- Target Recruit Count
- 30
- Registration Number
- NCT05667545
- Locations
- 🇪🇬
Faculty of Dentistary - Al-Azhar University, Cairo, Egypt
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.